Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 8/20 | 0.47 |
| ▸ | SLC40A1 | Q9NP59 | 5/20 | 0.46 |
| ▸ | CKS1B | P61024 | 3/20 | 0.46 |
| ▸ | SKP2 | Q13309 | 3/20 | 0.46 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.45 |
| ▸ | METAP1 | P53582 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3981261 | 0.86 | ALDH1A1 (0.58) | METAP2SLC40A1METAP1ALDH1A1GAA | |
| SCHEMBL3979712 | 0.83 | TP53 (0.47) | CKS1BSKP2ALDH1A1 | |
| SCHEMBL3985688 | 0.83 | CYP3A4 (0.49) | METAP2SLC40A1CKS1BSKP2GLO1 | |
| SCHEMBL3983177 | 0.80 | METAP2 (0.67) | METAP2SLC40A1CKS1BSKP2GLO1 | |
| SCHEMBL3981344 | 0.79 | METAP2 (0.56) | METAP2METAP1ALDH1A1GAAHTT | |
| SCHEMBL3985468 | 0.78 | METAP2 (0.76) | METAP2 | |
| SCHEMBL3984405 | 0.77 | METAP2 (0.73) | METAP2SLC40A1CKS1BSKP2GLO1 | |
| SCHEMBL25140692 | 0.73 | ACLY (0.52) | METAP2SLC40A1GLO1 | |
| SCHEMBL30806174 | 0.73 | ACLY (0.52) | METAP2SLC40A1GLO1 | |
| SCHEMBL16496135 | 0.73 | ACLY (0.58) | METAP2SLC40A1CKS1BSKP2GLO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7491718-B2 | Sulfonamides having antiangiogenic and anticancer activity | ABBOTT LABORATORIES (US) | 2009-02-17 | — | — | US | disclosed |
| EP-1549613-A1 | SULFONAMIDES HAVING ANTIANGIOGENIC AND ANTICANCER ACTIVITY | Abbott Laboratories (US) | 2005-07-06 | — | — | EP | disclosed |
| US-20040167128-A1 | Sulfonamides having antiangiogenic and anticancer activity | ABBVIE INC. | 2004-08-26 | — | — | US | disclosed |
| US-20040157836-A1 | Sulfonamides having antiangiogenic and anticancer activity | ABBOTT LABORATORIES | 2004-08-12 | — | — | US | disclosed |
| WO-2004033419-A1 | SULFONAMIDES HAVING ANTIANGIOGENIC AND ANTICANCER ACTIVITY | ABBOTT LABORATORIES (US) | 2004-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167128-A1 | Sulfonamides having antiangiogenic and anticancer activity | METAP2, METAP1, DNPEP | METAP2 1/4885SLC40A1 3138/4885CKS1B 2502/4885 |
| US-20040157836-A1 | Sulfonamides having antiangiogenic and anticancer activity | METAP2, METAP1, DNPEP | METAP2 1/4885SLC40A1 3138/4885CKS1B 2502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.